Back to top

JonesTrading Keeps Their Buy Rating on Y-Mabs Therapeutics (YMAB)

In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The company’s s...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Y-mAbs Therapeutics, Inc. (YMAB)